Monopar Therapeutics (MNPR) Other financing activities (2021 - 2025)

Monopar Therapeutics (MNPR) has 5 years of Other financing activities data on file, last reported at $544800.0 in Q4 2025.

• For the quarter ending Q4 2025, Other financing activities changed N/A year-over-year to $544800.0; the trailing twelve-month figure through Dec 2025 stood at $565171.0 (up 672722.62% YoY), and the FY2025 full-year result was $565171.0, up 672722.62% from the prior year.
• Other financing activities improved to $544800.0 in Q4 2025, from $214.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $1.7 million in Q3 2023 to a low of -$1.7 million in Q4 2023.
• A 5-year average of $58290.2 and a median of $2462.0 in 2025 frame the typical range for Other financing activities.
• Across the five-year window, Other financing activities surged 1322305.47% in 2023 and jumped 5507.14% in 2025, its largest moves.
• Tracing MNPR's Other financing activities over 5 years: stood at $17478.0 in 2021, then plunged by 99.27% to $128.0 in 2022, then plunged by 1322505.47% to -$1.7 million in 2023, then soared by 100.0% to $84.0 in 2024, then jumped by 648471.43% to $544800.0 in 2025.
• Business Quant data shows MNPR's Other financing activities at $544800.0 in Q4 2025, $214.0 in Q3 2025, and $4710.0 in Q2 2025.